Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European Lung Cancer Congress 2019 /
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC

10th - 13th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.04.19
Views: 756
Rating:

Prof Tony Mok - Chinese University of Hong Kong, Hong Kong

Prof Tony Mok speaks to ecancer at the European Lung Cancer Congress 2019 about the Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC).

Prof Mok emphasises that the importance of KEYNOTE-42 is that it will support the efficacy of patients over 50% PD-L1 expression, and also to see if there is an over-survival benefit at the 1% PD-L1 expression cutoff.

He outlines the data so far, and what this means for the use of single agent pembrolizumab for the 1-49% subgroup as a first line therapy, and the small group of patients that might be applicable for this treatment as opposed to the alternative KEYNOTE-189 regimen.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation